For most insured Americans, the 2026 pharmaceutical tariff will be a slow-moving story — costs may rise gradually through formulary changes and premium increases over months or years. But for two groups, the impact could be immediate and significant: uninsured patients paying cash prices and patients on high-deductible health plans (HDHPs) who pay out of pocket until they hit their deductible.
If you are in either group, here is what the tariff means for you specifically — and what you can do about it now.
Why Uninsured Patients Are Most Exposed
When you have insurance, your insurer negotiates drug prices with manufacturers and pharmacy benefit managers (PBMs). The insurer absorbs some of the cost increase, at least initially. When you pay cash — whether because you are uninsured, between jobs, or simply finding cash prices cheaper than your copay — you pay something closer to the actual acquisition cost of the drug.
The tariff hits at the acquisition cost level. The NADAC (National Average Drug Acquisition Cost) is the government's measure of what pharmacies pay for drugs. When a 100% tariff applies to a brand-name drug, it theoretically doubles the cost basis that cascades through the supply chain and into cash prices.
What data shows: A brand-name drug with a current NADAC of $500/month could see acquisition costs rise toward $1,000/month after a 100% tariff is applied. Cash prices at the pharmacy counter don't always track NADAC exactly — but they track direction.
Why HDHP Patients Are Particularly Vulnerable
High-deductible health plans shift costs onto patients until their deductible is met (often $1,500–$7,000 for an individual). Until you hit that threshold, you are essentially paying out of pocket — which means you pay the negotiated rate your insurer has set, not a flat copay.
If the tariff causes your insurer's negotiated price for a brand-name drug to rise, HDHP patients feel it directly and immediately in their pre-deductible spending. Insured patients with flat copays are shielded — they pay the same $40 copay regardless of whether the underlying drug cost went up. HDHP patients are not shielded in the same way.
Which Drugs to Watch
The highest-risk drugs for uninsured and HDHP patients are brand-name specialty medications from companies without MFN deals. These include:
- Pfizer drugs — Xeljanz, Vyndamax, Prevnar (Pfizer is not an Annex III company)
- J&J drugs — Stelara, Tremfya, Darzalex
- Bayer drugs — Xarelto, Eylea
- Takeda drugs — Vyvanse, Entyvio, Trintellix
Drugs from the 13 Annex III MFN companies (AbbVie, Merck, Novo Nordisk, Eli Lilly, etc.) pay 0% and are lower risk even for uninsured patients.
Generics are completely safe. If you're on any generic drug, the tariff does not apply regardless of your insurance status.
Practical Steps to Protect Yourself
1. Switch to generics now if possible.
This is the single most effective step. Ask your doctor whether a generic exists for your brand-name drug. Generics are exempt from the tariff at 0% — your cost doesn't change, regardless of what happens to brand prices.
2. Use Cost Plus Drugs or GoodRx for cash prices.
Mark Cuban's Cost Plus Drugs prices many generics at $3–15/month. GoodRx aggregates pharmacy discount prices. For generics especially, these tools often beat insurance out-of-pocket costs — and neither is affected by the tariff.
3. Request 90-day supplies before effective dates.
Before July 31 (for MFN company drugs) or September 29 (for all others), ask your doctor for a 90-day prescription. A 90-day fill at current pricing buys you time to evaluate options.
4. Look into patient assistance programs.
NeedyMeds, RxAssist, and manufacturer patient assistance programs (PAPs) offer free or deeply discounted brand-name drugs to patients below income thresholds. These programs exist independent of tariff status.
5. Check MFN deal status.
Use the RxTariff MFN deal tracker and drug search tool to confirm whether your specific drug comes from an Annex III company. If it does, you are protected regardless of insurance status.
The Bottom Line
The 2026 drug tariff is not the same risk for everyone. Insured patients with flat copays are largely insulated in the short term. Uninsured patients and HDHP patients who pay acquisition-cost-linked prices are at the front of the exposure line. The good news: the steps to protect yourself — switching to generics, using cost tools, securing 90-day supplies — are available right now, before the tariff clock runs out.